Article Correctness Is Author's Responsibility: Science News » Bench-to-Bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression

The article below may contain offensive and/or incorrect content.

FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug – a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.